Adherence to antiretroviral therapy is an important predictor of long-term treatment success. Adherence can be differentiated between early adherence challenges, that are about integrating pill-taking into daily life, and long-term adherence, where patients struggle to maintain clinical connections and interrupt clinical care and medication use. In resource-limited settings, treatment interruptions may be more useful predictors of patient outcome than pill-taking alone. Interventions that are aimed at providing support to patients and their individual challenges to prevent interruptions in treatment and care may have a greater impact over time on clinically important outcomes than interventions targeted only at pill-taking behaviours.
References
1.
HoggR.S., HeathK., BangsbergD.Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS2002; 16: 1051–1058.
2.
OyugiJ.H., Byakika-TusiimeJ., RaglandK.Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS2007; 21: 965–971.
3.
PatersonD.L., SwindellsS., MohrJ.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med2000; 133: 21–30.
4.
LimaV.D., BangsbergD.R., HarriganP.R.Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr2010; 55: 460–465.
5.
BangsbergD.R.Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis2006; 43: 939–941.
6.
MeresseM., CarrieriM.P., LaurentC.Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther2013; doi: 10.3851/IMP2535.
7.
MillsE.J., NachegaJ.B., BuchanI.Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA2006; 296: 679–690.
8.
AdakunS.A., SiednerM.J., MuzooraC.Higher baseline CD4 count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr2012; in press.
9.
GovindasamyD., FordN., KranzerK.Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS2012; 26: 2059–2067.
10.
MillsE.J., NachegaJ.B., BangsbergD.R.Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med2006; 3: e438.
11.
AhonkhaiA.A., NoubaryF., MunroA.Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS ONE2012; 7: e32993.
12.
KranzerK., FordN.Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health2011; 16: 1297–1313.
13.
WareN.C., WayattM.A., GengE.Missed clinic visits and disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study. PLoS Med2012; in press.
14.
Nakimuli-MpunguE., BassJ.K., AlexandreP.Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav2012; 16: 2101–2118.
15.
FordN., DarderM., SpelmanT., MacleanE., MillsE., BoulleA.Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS ONE2010; 5: e10460.
16.
RosenblumM., DeeksS.G., van der LaanM., BangsbergD.R.The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE2009; 4: e7196.
17.
BärnighausenT., ChaiyachatiK., ChimbindiN., PeoplesA., HabererJ., NewellM.L.Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis2011; 11: 942–951.
18.
ChungM.H., RichardsonB.A., TapiaK.A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med2011; 8: e1000422.
19.
Pop-ElechesC., ThirumurthyH., HabyarimanaJ.P.Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS2011; 25: 825–834.
20.
LesterR.T., RitvoP., MillsE.J.Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet2010; 376: 1838–1845.
21.
FordN., NachegaJ.B., EngelM.E., MillsE.J.Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet2009; 374: 2064–2071.
ChangL.W., KagaayiJ., NakigoziG.Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS ONE2010; 5: e10923.
24.
DecrooT., TelferB., BiotM.Distribution of antiretroviral treatment through self-forming groups of patients in Tete province, Mozambique. J Acquir Immune Defic Syndr2011; 56: e39–344.
25.
LachettiC., IoannidisJ.P., GuyattG.Surprising Results of Randomized Trials. In GuyattG., RennieD., MeadeM.O., CookD.J. (Editors). Users’ Guides to the Medical Literature.Chicago: AMA Press2008; pp. 113–149.
26.
LambdinB.H., MicekM.A., KoepsellT.D.Patient volume, human resource levels, and attrition from HIV treatment programs in central Mozambique. J Acquir Immune Defic Syndr2011; 57: e33–e39.
27.
BissonG.P., GrossR., BellamyS.Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med2008; 5: e109.
28.
HabererJ.E., KahaneJ., KigoziI.Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav2010; 14: 1340–1346.
